Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Results
Phase 1
This trial looked at adding romidepsin to azacitidine for people with acute myeloid leukaemia (AML). It was for people who:
couldn’t have standard chemotherapy for AML and
had already had a lot of treatment for AML
The trial was open for people to join between 2013 and 2017. The team published the results in 2021.
Recruitment start: 30 September 2013
Recruitment end: 6 October 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Charles Craddock
Blood Cancer UK
Celgene Ltd
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Birmingham
Last reviewed: 11 June 2024
CRUK internal database number: 9878
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
